Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PIK3CA H1047X |
| Therapy | Bortezomib + Temsirolimus + Topotecan |
| Indication/Tumor Type | small intestine adenocarcinoma |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA H1047X | small intestine adenocarcinoma | predicted - resistant | Bortezomib + Temsirolimus + Topotecan | Case Reports/Case Series | Actionable | In a clinical study, the combination of Torisel (temsirolimus) plus Velcade (bortezomib) and Hycamtin (topotecan) resulted in progressive disease in a patient with small intestine adenocarcinoma harboring a PIK3CA H1047 mutation (PMID: 21216929). | 21216929 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (21216929) | PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. | Full reference... |